Breast neoplasm

Researchers are testing whether combining ribociclib and belinostat can help people with metastatic triple-negative breast cancer or recurrent ovarian cancer. The trial starts by finding the safest dose of the drug pair, then expands to see how well it works in breast cancer pati…

This phase 2 trial tests whether a 12-week course of docetaxel plus trastuzumab after surgery can keep small (≤1 cm), node-negative HER2-positive breast cancer from returning. Women who have completed radical surgery for this type of cancer receive the two drugs every three weeks…

This study tests a new treatment called 4SCAR-CD44v6 T cells for people with cancers that have a specific protein called CD44v6. The therapy uses a patient's own immune cells, modified to better recognize and attack cancer cells. The trial will enroll 100 participants to check sa…

This early-stage trial tests a new drug, GDC-0587, alone or with another drug (giredestrant), in people with advanced ER-positive, HER2-negative breast cancer whose cancer worsened after prior CDK4/6 inhibitor therapy. The study aims to find safe doses and check for side effects.…

This early-stage study tests a new oral drug, BBI-940, in people with advanced or metastatic breast cancer that has not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The study aims to find the safest dose and check for s…

This trial explores whether adding counseling, cognitive behavioural therapy, or hypnotherapy to nicotine replacement therapy can help cancer patients quit smoking before their surgery. The study includes adults with breast, digestive, gynecologic cancer, or melanoma who smoke da…

This trial tests whether adding an experimental immunotherapy called eftilagimod alpha to standard chemotherapy (paclitaxel) can help people with HER2-negative metastatic breast cancer live longer. The study first finds the best dose of eftilagimod alpha, then compares the combin…

This trial offers continued treatment with poziotinib for people with non-small cell lung cancer or breast cancer who have already benefited from the drug in a previous study. The goal is to monitor safety and see how long the cancer remains controlled with extended use. Only pat…

This study tested a new drug called GEN1047 in people with advanced solid tumors (breast, endometrial, ovarian, or lung cancer) who had no other treatment options. The goal was to check safety, side effects, and how the body processes the drug. The study was terminated early, but…

This trial tests a combination of two drugs, elacestrant and onapristone, in people with a specific type of advanced or metastatic breast cancer that is fueled by the hormones estrogen and progesterone. The goal is to see if blocking both hormone signals at once is safe and can s…

This study looks at women who have had breast surgery and radiation before and need another breast surgery. Because radiation increases the risk of wound complications, the researchers want to see if giving a week of antibiotics or using a wound VAC (a special dressing) helps pre…

This study looks at genetic changes in postmenopausal women with a common type of advanced breast cancer (HR+ HER2-). Participants first receive ribociclib plus letrozole; those with a specific mutation (PIK3CA) may later switch to alpelisib plus fulvestrant. The goal is to track…

This early-phase trial tested a combination of two drugs—nab-paclitaxel (a chemotherapy) and alpelisib (a targeted therapy)—in patients with triple-negative breast cancer that had specific genetic changes (PIK3CA or PTEN) and didn't respond to standard treatment. The goal was to …

This trial investigates whether adding bevacizumab (Avastin) to standard first-line chemotherapy plus trastuzumab (Herceptin) helps people with HER2-positive metastatic breast cancer. Participants receive either bevacizumab or a placebo alongside their regular treatment. The main…

This phase 3 trial aimed to compare two drugs, ribociclib and palbociclib, in people with a specific type of advanced breast cancer (HR+/HER2- with HER2-enriched features). Participants received one of the drugs combined with hormone therapy. The goal was to see which combination…

This early-stage study tested the safety and best dose of combining the drugs RAD001 and docetaxel in 15 people with metastatic breast cancer. The goal was to find a dose that is tolerable while potentially controlling the disease. The study was terminated early, so results are l…

This study looks at whether the beta-blocker carvedilol can prevent or treat heart problems in breast cancer patients receiving HER2-targeted therapy. About 184 adults with HER2-positive breast cancer will be randomly assigned to take carvedilol either preventatively or only afte…

This study tested whether adding a HER2-targeting vaccine (VRP-HER2) to the immunotherapy drug pembrolizumab could boost the immune system's attack on advanced HER2-positive breast cancer. Eight participants were randomly assigned to receive the vaccine alone, pembrolizumab alone…

This early-stage trial tested a new drug, azenosertib, combined with two standard cancer drugs (carboplatin and pembrolizumab) in people with metastatic triple-negative breast cancer. The goal was to find a safe dose and see if the combination shrank tumors. Only 7 people took pa…

This phase 3 trial tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy and HER2-targeted therapy could help people with HER2-positive breast cancer that has spread. The study enrolled 190 participants but was terminated early, so the full results ar…

This early-phase study tested a new treatment for people with advanced breast cancer that had stopped responding to standard therapies. The treatment combined a patient's own engineered immune cells (CLBR001) with an antibody drug (ABBV-461). The study aimed to find the safest do…

This phase 2 study tested a drug called GDC-0084 combined with trastuzumab (Herceptin) in 17 people with HER2-positive breast cancer that had spread to the brain. The goal was to see if the combination could shrink or control brain tumors. Unfortunately, the trial was terminated …

This phase III trial compared two radiation strategies for cancer that had spread to the brain and returned in new spots after initial radiosurgery. One group received focused radiation only to the new tumors, while the other received whole brain radiation that avoided the memory…

This early-phase trial tested combinations of the drugs bevacizumab and temsirolimus, sometimes with valproic acid or cetuximab, in 154 people with advanced cancers or certain non-cancerous but progressive diseases. The main goal was to find safe doses and look for any signs that…

This early-phase trial tested a combination of two oral drugs, BKM120 and lapatinib, in 24 people with HER2-positive breast cancer that had stopped responding to trastuzumab. The goal was to find a safe dose and see if the combination could shrink tumors. The study was terminated…

This phase 2 trial tested whether combining metformin (a diabetes drug) with doxycycline (an antibiotic) could help treat localized breast and uterine cancers. The study enrolled 29 people who were scheduled for surgery. Researchers looked at changes in certain proteins in the tu…

This study tested a new drug (LY2780301) combined with standard chemotherapy (paclitaxel) in people with advanced HER2-negative breast cancer that had spread or couldn't be removed by surgery. The goal was to find the safest dose and see if the combination could shrink tumors. Th…

This study looked at whether taking vitamin D could change certain genes in breast cancer tumors, and if a woman's weight affected those changes. Researchers gave 41 women with breast cancer either a low or high dose of vitamin D before surgery. The goal was to see if vitamin D c…

This study compared two types of radiation given after breast-conserving surgery for early-stage breast cancer: 3D conformal radiation (external beams) and internal brachytherapy (radioactive material placed in the breast). Only 6 women took part before the trial was stopped earl…

This phase 2 trial aimed to see if trastuzumab deruxtecan (Enhertu) could help people with HER2-positive breast cancer that had spread and did not respond to standard first-line therapy. Only 2 participants were enrolled before the study was terminated early, so the results are v…

This early-stage study tested a new drug called CPO-100 in 34 adults with advanced solid tumors that had not responded to at least two prior treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.

This early-phase trial tested two oral drugs, abemaciclib and elacestrant, in women with a type of breast cancer (HR+/HER2-) that had spread to the brain. The goal was to see if the combination was safe and could shrink brain tumors. However, the study was stopped early after enr…

This phase 2 trial tested the chemotherapy drug ixabepilone in 13 patients with metastatic breast cancer that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or slow the disease. The study was terminated early, so the full result…

This study tested a surgical method to prevent lymphedema (arm swelling) in people having lymph nodes removed for breast cancer or melanoma. The technique, called axillary reverse mapping with lympho-venous bypass, aims to preserve arm drainage while removing cancer-affected node…

This study tested a drug called abemaciclib in 27 people with a specific type of advanced breast cancer (triple-negative, retinoblastoma-positive). The goal was to see if the drug could shrink tumors or slow the cancer's growth. The trial was terminated early, so results are limi…

This early-phase trial tested a combination of targeted drugs (neratinib, pertuzumab, trastuzumab) and chemotherapy (paclitaxel, doxorubicin, cyclophosphamide) in 34 people with advanced or inflammatory breast cancer. The goal was to find the best dose and see if the combo could …

This early-phase trial tested a combination of two drugs—infigratinib (a targeted therapy) and tamoxifen (a hormone therapy)—in people with a specific type of advanced breast cancer (hormone receptor-positive, HER2-negative, with FGFR gene changes). The goal was to find a safe do…

This early study tested combining high-intensity focused ultrasound (HIFU) with the immunotherapy drug pembrolizumab (Keytruda) in 13 people with metastatic breast cancer. The goal was to see if the ultrasound could help the immune system better recognize and attack tumors. The t…

This early-phase trial tested an experimental drug called TAK-500, alone or with the immunotherapy pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The stud…

This phase 2 trial tested the drug neratinib, alone or with fulvestrant, in 21 people with HER2-positive, ER-positive metastatic breast cancer. The study aimed to see if the combination could slow cancer growth. However, the trial was terminated early, meaning we have limited dat…

This early-phase trial tested a radioactive drug designed to seek out and destroy cancer cells in people with advanced solid tumours that had stopped responding to other treatments. The drug targets a protein called IGF-1R found on many cancer cells. The study aimed to find a saf…

This study looked at whether women with a certain type of early-stage breast cancer (HER2-positive, low-risk) could avoid surgery if their tumors completely disappeared after standard drug treatment. Only 5 women enrolled before the study was stopped. The goal was to see if a spe…

This study tested whether adding a short course of focused radiation to standard chemotherapy before surgery could improve outcomes for women with aggressive breast cancers. The trial enrolled 362 patients with luminal B or triple-negative breast cancer that was too large for ini…

This early-phase trial tested a combination of hyperthermia (heating the tumor area) and the drug olaparib in 3 patients with breast cancer that had returned on the chest wall. The goal was to see if the combination was safe and could slow tumor growth. The study was terminated e…

This study tested a combination of two drugs—pembrolizumab (an immunotherapy) and mifepristone (a hormone blocker)—in people with advanced HER2-negative breast cancer. The goal was to see if the combination could shrink tumors. The study was stopped early after enrolling 24 parti…

This study tested whether adding a drug called ATRA (all-trans retinoic acid) to the standard hormone therapy anastrozole could shrink tumors more effectively in postmenopausal women with a common type of early breast cancer (HR-positive/HER2-negative). The trial was planned for …

This study tested a new type of nipple reconstruction using a graft made from donated human nipples. Six breast cancer survivors who had already undergone breast reconstruction surgery received the graft. The goal was to see if the graft was safe and how long it took to heal, as …

This study tested a new drug combination (TQB3912, fulvestrant, and TQB3616) in people with advanced HR-positive, HER2-negative breast cancer. The goal was to find the best dose and see if the treatment shrank tumors or slowed cancer growth. The trial was stopped early after enro…

This study tested a combination of three drugs—tucatinib, trastuzumab, and vinorelbine—in 13 people with HER2-positive breast cancer that had spread or could not be surgically removed. The goal was to see how many patients' tumors shrank or disappeared. The trial was terminated e…

This study tested a new oral drug called amcenestrant for postmenopausal women with a certain type of advanced breast cancer (ER+/HER2-). The goal was to find safe doses and see if it works alone or with other drugs. The trial was stopped early, but the results help researchers u…

This study tested a new drug called BDC-1001, given alone or with another drug (pertuzumab), in people with advanced HER2-positive breast cancer that had already been treated with multiple therapies, including trastuzumab deruxtecan. The goal was to see if the drug could shrink t…

This study tested an experimental drug (PF-06873600) taken by mouth, alone or with hormone therapy, in people with advanced breast or ovarian cancers. The goal was to check safety and see if the drug could shrink tumors. The trial was stopped early, but results help guide future …

This phase 2 trial tested the drug futibatinib (TAS-120), alone or with the hormone therapy fulvestrant, in people with metastatic breast cancer that has specific FGFR gene changes. The study aimed to see if the treatment could shrink tumors or slow cancer growth. However, the tr…

This study looked at whether mammography and breast MRI could help identify patients with early-stage breast cancer (DCIS) who could safely receive a single dose of radiation during surgery, instead of weeks of daily radiation afterward. The goal was to avoid repeat surgeries and…

This early-stage trial tested an experimental drug called NUV-868, alone or with other cancer drugs, in 82 adults with advanced solid tumors (including ovarian, pancreatic, prostate, and breast cancers). The goal was to find safe doses and check for early signs of effectiveness. …

This study tested a drug called niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific genetic change called a PALB2 mutation. The goal was to see if the drug could shrink tumors or slow cancer growth. The study was stoppe…

This study tested an experimental drug called INCB057643 in 137 people with advanced cancers that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects, both when given alone and with other cancer drugs. The trial was terminate…

This study looked at menopausal women over 50 with very small breast cancers (less than 10 mm). It compared standard surgery plus armpit lymph node removal versus surgery alone to see if skipping the extra procedure was safe. The goal was to reduce side effects like arm swelling …

This early-stage study tested a new drug called ACTM-838 in 10 people with advanced solid tumors that no longer responded to standard treatments. The main goals were to check safety and find the right dose. The study was stopped early, so results are limited.

This early-stage trial tested a new drug called TAS2940 in 29 people with advanced solid tumors (like lung, breast, or brain cancer) that had specific genetic changes (EGFR or HER2). The goal was to find a safe dose and see if the drug could shrink tumors. The study was stopped e…

This study tested a combination of two drugs, ZEN003694 and talazoparib, in people with triple-negative breast cancer who do not have BRCA gene mutations. The trial aimed to see if the combo could shrink tumors or stop them from growing. It included 115 participants but was termi…

This study looked at adding a drug called copanlisib to standard targeted therapy (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that had spread and had specific gene changes (PIK3CA or PTEN). The goal was to see if the combination was safe and could hel…

This study looked at whether a specific type of exercise, combining aerobic and resistance training in short bursts, could improve metabolic health in overweight or obese breast and prostate cancer survivors who had finished treatment. The goal was to reduce insulin resistance an…

This early-phase trial tested whether adding donor natural killer (NK) cells to the standard antibody drugs trastuzumab and pertuzumab could help people with advanced HER2-positive breast cancer that had stopped responding to other treatments. Only 2 participants were enrolled be…

This Phase 2 study tested two doses of amcenestrant, a new oral drug that blocks estrogen receptors, against letrozole, a standard hormone therapy, in 105 postmenopausal women with ER-positive, HER2-negative breast cancer. The goal was to see if amcenestrant could better reduce t…

This study aimed to see if a new drug called amcenestrant could help prevent breast cancer from coming back in people with hormone receptor-positive early breast cancer who had side effects from standard aromatase inhibitor therapy. It was designed to compare amcenestrant against…

This early-stage trial tested an experimental drug called SAR443216 in 44 adults with advanced HER2-expressing solid tumors (such as breast, lung, or gastric cancer) that had come back or stopped responding to standard treatments. The study aimed to find a safe dose and check for…

This early-stage trial tested a new drug called BDC-1001, alone or with the immunotherapy nivolumab, in 175 people with advanced HER2-positive cancers (like breast, colorectal, and stomach cancers) that had stopped responding to other treatments. The study aimed to check safety a…

This phase 3 trial tested whether a new drug called amcenestrant (which blocks estrogen) combined with palbociclib could help people with advanced ER+/HER2- breast cancer live longer without their cancer growing. Over 1,000 participants who had not yet received treatment for adva…

This phase 3 trial tested a drug called PD G 506 A that makes cancer cells glow under a special camera during breast-conserving surgery. The goal was to help surgeons see and remove leftover cancer in real time, reducing the need for a second operation. The study enrolled 57 wome…

Researchers are testing a nonlinear microscope (NLM) that images breast tissue during lumpectomy without the usual slide preparation. The goal is to see if the NLM can help surgeons find close or positive margins right away, so fewer patients need a second operation. The trial en…

This pilot study compares contrast-enhanced digital breast tomosynthesis (CE-DBT) to standard MRI in 20 women with known breast lesions. Researchers want to see if CE-DBT can give doctors similar confidence in identifying suspicious areas. If it works, it might offer a quicker or…

This study tested a special PET/CT scan using a radioactive tracer called FES to see estrogen receptor activity in women with advanced, hormone-resistant breast cancer. The goal was to see if the scan could predict how well a new hormone therapy would work. Only 6 people were enr…

This early-phase trial tested a radioactive imaging agent called 68GaNOTA-Anti-MMR-VHH2 to see if it could safely highlight tumors on PET scans. It involved 13 adults with advanced solid tumors, breast cancer, or melanoma. The study was terminated early, so we have limited inform…

This study tested a new, fast, and low-cost MRI method for breast cancer screening in women with dense breasts or moderate risk. The goal was to see if this MRI could find cancers earlier and more accurately than standard mammograms. The study enrolled 166 women and compared MRI …

This study tested whether a special type of MRI called DWIBS can better identify suspicious breast lesions found on mammograms and ultrasounds. The goal was to see if it could accurately tell benign from malignant lesions and potentially reduce false-positive biopsies. Only 11 wo…

This early-phase trial tested a radioactive imaging agent called 68Ga-FF58 in 14 adults with certain advanced solid tumors (glioblastoma, brain metastases from breast cancer, gastroesophageal cancer, or pancreatic cancer). The goal was to see if the agent could help detect these …

This study tested a new 3D ultrasound technique called acoustic angiography to improve imaging of breast and thyroid tumors. Researchers planned to enroll 45 people, including healthy volunteers and patients scheduled for biopsy. The study was stopped early due to funding problem…

This study looked at whether giving radiation to the brain could prevent cancer from spreading there in people with HER2-positive breast cancer that had already spread to other organs. Participants were receiving trastuzumab (Herceptin) plus chemotherapy. The study was stopped ea…

This study aimed to see if a tamoxifen skin gel could work as well as the pill to lower breast cancer risk in women with certain high-risk breast conditions. The trial enrolled 65 women and compared short-term changes in breast tissue. However, the study was terminated early, so …

This pilot study aimed to see if giving heart medications (carvedilol and empagliflozin) to women starting HER2-targeted therapy for breast cancer could prevent heart damage. The study planned to enroll 20-40 participants but was terminated early after enrolling only 7. The goal …

Researchers are testing a synbiotic formula called BLHK03 to see if it can reduce hair loss caused by chemotherapy in women with breast cancer. The trial includes 7 women with stage I to III breast cancer who are scheduled for chemotherapy with anthracycline or taxane drugs. Part…

This pilot study tests whether a wearable EEG headband (MUSE-S) that guides meditation can help breast cancer survivors who struggle with anxiety and insomnia. Twenty participants will use the headband at home, and researchers will track how often they use it and whether it impro…

This study tests whether a headband with special semiconductors can help with memory and thinking problems (often called 'chemo brain') in people who have had breast or gynecologic cancer. About 50 participants will wear either the active headband or a placebo version for 18 hour…

This study tested whether the sleep medication suvorexant (20 mg) could help breast cancer survivors who have trouble sleeping. Participants were postmenopausal women taking hormone-blocking drugs. The study was stopped early after enrolling only 5 people, so results are limited.

This study is testing whether giving women with early-stage breast cancer two easy-to-read booklets can help lower their anxiety after diagnosis. The booklets explain the disease and treatments in a gentle, clear way. About 60 women will take part, and researchers will measure ho…

This study investigates whether giving patients personalized, secure access to a web platform with an explanatory video about their upcoming breast cancer surgery can lower their anxiety. Participants are women with breast cancer scheduled for lumpectomy, oncoplasty, or mastectom…

This study tested a smartphone app called 'Bouge' to see if it could help women with non-metastatic breast cancer increase their daily steps while on weekly Taxol chemotherapy. The goal was to add 3,000 steps per day over 90 days. Only 23 people enrolled, and the trial was stoppe…

This study tested a program called Y-AMBIENT designed to improve quality of life for young African American women who finished treatment for early or late-stage breast cancer. The program included educational sessions and check-ins, compared to a control group that received a coo…

This study tested whether a continuous drip of the local anesthetic ropivacaine into the surgical wound after mastectomy could improve pain control and speed up recovery. The trial planned to enroll 59 women and follow them at home after discharge. However, the study was terminat…

This study looked at whether a mechanical stimulation technique can reduce pain and improve shoulder mobility better than standard massage in women who had a total mastectomy with lymph node removal. About 80 participants were planned, all needing physiotherapy after surgery. The…

This study tested whether early, personalized support from a psychologist could help women with breast cancer return to work more successfully than standard support. The study included 128 women who had surgery and chemotherapy. Unfortunately, the trial was stopped early, so we h…

This study tested a text-message-based diet program called Txt4fasting for people with breast or lung cancer that spread to the brain. The goal was to see if eating only during certain hours could reduce thinking and memory problems after radiation. Only 1 person enrolled before …

This study tested a smartphone app called HeartPhone that appears on the lock screen to encourage physical activity in breast cancer, leukemia, and lymphoma survivors. Participants used the app for 3 months and wore a Fitbit to track activity. The goal was to see if the app could…

This study tested a cream called dermaprazole (a form of esomeprazole) to see if it could prevent or reduce skin burns caused by radiation therapy in women who had mastectomy for breast cancer. Only 3 women were enrolled before the trial was stopped early. The goal was to check s…

This study tested whether a web-based symptom tracking tool could improve quality of life for people with early-stage breast or colorectal cancer receiving chemotherapy. Participants were randomly assigned to either use the online tool to report symptoms between clinic visits or …

This study tested whether wearing a special chest bandage after mastectomy could reduce the number of times doctors need to drain fluid buildup (seroma). Half of the 60 participants got the bandage plus standard drainage, while the other half had only drainage. The study was stop…

This study tested whether applying tranexamic acid (TXA) directly to the surgical wound during breast removal and reconstruction can reduce bleeding (hematoma) and fluid collections (seroma). These complications can delay healing and cancer treatments. The trial enrolled 23 women…

This study tested a digital health app called medidux™ in 196 people with HER2-positive breast cancer. The app was used for up to 16 weeks during chemotherapy to help track and manage side effects. The goal was to see if using the app reduced the number of severe side effects. Ho…

This study looked at whether COVID-19 caused more financial hardship for Women of Color compared to other women who decided not to join a breast cancer screening trial. Researchers surveyed 14 women about job loss, income drops, and housing or food insecurity. The goal was to und…

This study tests whether community health forums called WE-CARE can help more rural and low-income women get screened for breast cancer and join clinical trials. The forums include educational sessions, survivor storytelling, and patient navigation to address barriers. Researcher…

This study investigates whether levels of certain blood proteins—VEGF, soluble HER2, and VCAM-1—change over time in women with hormone-insensitive breast cancer. It compares women who receive maintenance chemotherapy with those who do not, and also looks at whether these protein …

This study looked at 42 women with advanced breast cancer who had chemotherapy before surgery. It compared three imaging tests—PET-CT, ultrasound, and MRI—to see which one best measures leftover tumor. The goal was to help doctors choose the right surgery, but the study was stopp…

This study aimed to find inherited gene changes in people diagnosed with cancer at a young age, including breast, ovarian, colorectal, and pediatric cancers. Researchers used a special test to look at 200 genes linked to cancer in 289 participants. The goal was to better understa…

This observational study aimed to measure different types of immune cells in women with advanced breast cancer that has spread. Researchers collected blood and leftover tumor samples to see how these cells change over time. The study was terminated early, so only a small number o…

This study looked at whether adding a polygenic risk score (a genetic test) to standard breast cancer risk tools helps African American and Hispanic women make better decisions about screening and prevention. Researchers enrolled 19 women at higher risk for breast cancer. The stu…

This study explored whether a wearable brain scanner (fNIRS) could objectively measure pain in cancer patients and survivors. It also tested if virtual reality (VR) relaxation could help reduce pain. The study included 106 participants, including healthy volunteers and cancer pat…

This study aimed to find genetic and protein changes in breast cancer that could help predict how the disease behaves. Researchers collected tumor samples from 749 adults with breast cancer and analyzed them for gene activity and mutations. The study was stopped early, so results…

This study looked at whether body weight affects how breast cancer responds to aromatase inhibitors (AIs) like Anastrozole and Letrozole. Researchers gave standard doses of these drugs to 42 postmenopausal women with hormone-sensitive breast cancer before surgery. The goal was to…

This study looked at how breast cancer stem cells—cells that can resist treatment and cause cancer to return—emerge during chemotherapy. Researchers collected blood and tumor samples from 56 women before, during, and after treatment to analyze genetic changes. The goal was to und…

This study aimed to understand how chemotherapy impacts the ability to have children in young women (ages 18-37) with breast cancer. Researchers measured ovarian reserve (egg supply) using hormone levels and follicle counts before, during, and up to 24 months after treatment. The…

This study looked at how a single round of chemotherapy affects the muscles of women with early-stage breast cancer. Researchers compared three common chemo regimens: paclitaxel alone, paclitaxel plus trastuzumab, and paclitaxel plus carboplatin. They took muscle biopsies and mea…

This study aimed to closely monitor heart function in women with breast cancer receiving common chemotherapy drugs (epirubicin, cyclophosphamide, paclitaxel) to see when heart damage first appears. Researchers planned to use advanced ultrasound and exercise tests to detect early …

This was an observational study that planned to track side effects, especially high blood sugar, in patients taking alpelisib (Piqray) plus fulvestrant for a type of advanced breast cancer. It included postmenopausal women and men whose cancer had a specific gene mutation (PIK3CA…

This study aimed to test a simpler consent process to compare three standard chemotherapy regimens for triple-negative breast cancer. Only 2 participants enrolled before the trial was terminated early, so it could not determine which treatment works best. The main goal was to see…

This study tested whether giving a short course of immunotherapy (atezolizumab, alone or with other drugs) before standard treatment could increase immune cell activity in early-stage breast cancer. It involved 33 patients with triple-negative or HER2-positive breast cancer. The …

This observational registry aims to learn about the health, wellbeing, and needs of people who were diagnosed with cancer between ages 18 and 39. Participants complete surveys every 6 to 12 months about anxiety, depression, social support, and financial distress. The registry als…

This study looked at whether giving the drug palbociclib before surgery could cause changes in breast tissue in people with ductal carcinoma in situ (DCIS), a very early form of breast cancer. It planned to enroll 24 participants, but was stopped early after only 17 joined. The m…